KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Non-Current Debt (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Non-Current Debt for 7 consecutive years, with $8.6 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 29.57% to $8.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.6 billion through Dec 2025, up 29.57% year-over-year, with the annual reading at $8.6 billion for FY2025, 29.57% up from the prior year.
  • Non-Current Debt hit $8.6 billion in Q4 2025 for Royalty Pharma, roughly flat from $8.6 billion in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $8.6 billion in Q4 2025 to a low of $5.8 billion in Q1 2021.
  • Historically, Non-Current Debt has averaged $6.7 billion across 5 years, with a median of $6.6 billion in 2024.
  • Biggest five-year swings in Non-Current Debt: dropped 13.78% in 2023 and later grew 29.58% in 2025.
  • Year by year, Non-Current Debt stood at $7.1 billion in 2021, then fell by 13.77% to $6.1 billion in 2022, then increased by 0.27% to $6.1 billion in 2023, then grew by 7.81% to $6.6 billion in 2024, then rose by 29.57% to $8.6 billion in 2025.
  • Business Quant data shows Non-Current Debt for RPRX at $8.6 billion in Q4 2025, $8.6 billion in Q3 2025, and $7.0 billion in Q2 2025.